NCT01956630

Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT

Clinical Study of Genetically Modified Dendritic Cells Combining to Cytokine-Induced Killer Cells for Patients With Relapse Acute Leukemia After Allo-HSCT

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Affiliated Hospital to Academy of Military Medical Sciences · Academic / Other
• Sex: All
• Age: 8 Years – 61 Years
• Healthy volunteers: Not accepted

Summary

Allogeneic hematopoietic cell transplantation(Allo-HSCT) is currently an effective treatment for Acute leukemia (AL). Relapse after transplantation, being a main obstacle for patient survival, is so far treated by second transplantation and donor leukocyte infusion (DLI), which seems to have high risk and low survival. Need for a new medication on relapse is urgent. The immunotherapy using Dendritic cells (DCs) combined with cytokine induced killer (CIK) cells holds promise for the adjuvant treatment of AL to eradicate or control residual disease. This randomized study was conducted to evaluate the feasibility and effective of genetically modified DCs combining to CIK immunotherapy in relapse AL after allo-HSCT.

Conditions

• Acute Leukemia

Interventions

Type	Name	Description
BIOLOGICAL	Genetically modified DCs plus CIK cells
BIOLOGICAL	Donor leukocyte infusions (DLI)

Timeline

• Start date: 2013-09-01
• Primary completion: 2016-09-01
• Completion: 2016-12-01
• First posted: 2013-10-08
• Last updated: 2016-02-22

Locations

1 site across 1 country: China